Fund Industry Research Articles

A Study on Mutual Fund Industry Growth Potential in India

A Study on Mutual Fund Industry Growth Potential in India

Gambling preferences and fund company ownership: Evidence from China

This paper empirically tests the preference of China's public mutual funds for lottery-type equities, analyzing data from equity funds in the country's public mutual fund market from 2005 to 2022. The study finds that this gambling preference positively correlates with short-term fund performance, but negatively impacts long-term outcomes. Further investigation shows that the funds' propensity for gambling increases stock market volatility. However, fund company ownership can mitigate this risk amplification by implementing a risk-sharing structure. Additionally, a significant positive correlation exists between the mutual fund industry's gambling inclination and fund managers' optimism about future market movements. Finally, this article employs text analysis to explore the influence of gambling preferences from a non-quantitative information perspective, which helps control the investing behavior of institutional investors and enhances the real economy's access to the capital market.

Randomised study of the effects of sense of entitlement and conflict of interest contrarianism on researcher decision-making to work with the alcohol industry

BackgroundIt is well established that the tobacco industry used research funding as a deliberate tactic to subvert science. There has been little wider attention to how researchers think about accepting industry funding. We developed, then tested, hypotheses about two psychological constructs, namely, entitlement and conflict of interest contrarianism (CoI-C) among alcohol researchers who had previously received industry funding.MethodsA mixed-methods pilot study involved construct and instrument development, followed by an online survey and nested 3-arm randomised trial. We randomly allocated alcohol industry funding recipients to one of three conditions. In two experimental conditions we asked participants questions to remind them (and thus increase the salience) of their sense of entitlement or CoI-C. We compared these groups with a control group who did not receive any reminder. The outcome was a composite measure of openness to working with the alcohol industry.Results133 researchers were randomised of whom 79 completed the experiment. The posterior distribution over effect estimates revealed that there was a 94.8% probability that reminding researchers of their CoI-C led them to self-report being more receptive to industry funding, whereas the probability was 68.1% that reminding them of their sense of entitlement did so. Biomedical researchers reported being more open to working with industry than did psychosocial researchers.ConclusionHolding contrarian views on conflict of interest could make researchers more open to working with industry. This study shows how it is possible to study researcher decision-making using quantitative experimental methods.

РОБОТИЗАЦИЯ ПРОИЗВОДСТВА СЕЛЬСКОХОЗЯЙСТВЕННОЙ ТЕХНИКИ

Increasing labor productivity at agricultural engineering enterprises in modern conditions is impossible without the use of robots, which should replace human labor in technological operations with dangerous and harmful production processes. (Research purpose) The research purpose is evaluating the use of robotics by enterprises of the agricultural machinery industry in the production. (Materials and methods) Conducted an assessment of the use of robotics tools when visiting enterprises in the agricultural engineering industry. (Results and discussion) It has been established that for a sustainable presence and strengthening of their positions in the market, companies producing agricultural machinery are increasing the volume of research and development work on the designs and production technologies of modern machines. It was noted that an increase in labor productivity in modern conditions is impossible without the use of robots, which are designed to replace human labor at work with harmful and dangerous production factors in procurement, when cleaning blanks, with thermal and physical methods of surface treatment of products made of various materials, when painting, as well as in order to reduce defects. It was determined that the use of robotization tools by enterprises of the agricultural machinery industry does not exceed three percent of the total volume of technological operations performed. Robotics tools are used mainly in welding operations. Loading and unloading, replacement of working tools on numerically controlled machines, as well as many other technological operations remain practically not covered. (Conclusions) The conducted studies have shown that machine-building companies have large reserves for using robotics tools in performing technological operations in order to reduce production costs and increase labor productivity. As measures to support the introduction of robots into production, grants are allocated by the Russian Digital Economy and Skolkovo foundations, preferential loans through the industrial development Fund "Digitalization of Industry".

(017) FLIBANSERIN IMPROVES LIBIDO AND SEXUAL SATISFACTION IN WOMEN WITH BREAST CANCER ON ENDOCRINE THERAPY

Abstract Introduction Decreased libido is a distressful symptom during and after cancer treatment. This is the first prospective longitudinal study that investigates the use of flibanserin to treat decreased libido in breast cancer patients on endocrine therapy. Objective This study evaluates the efficacy of flibanserin as measured by change in desire, sexual function, and distress from sexual dysfunction. These outcomes are measured using the following validated instruments: Female Sexual Function Index (FSFI) both desire and total scores, Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) and patient distress via FSDS-R. Methods Forty-three women with stage 0-III ER+ breast cancer on endocrine therapy for at least 3 months who reported HSDD as defined by the DSM-IV and ISSWH consensus paper were enrolled on an IRB-approved prospective, longitudinal trial from both an academic center and an alliance community site. All patients took flibanserin 100mg nightly for 24 to 36 weeks. Patients were monitored closely for 52 weeks for adverse events, with medical exams and questionnaires at baseline, week 4, 8, 16, 24, 52 with optional week 36 appointments. Given the small sample size, descriptive, graphical, and nonparametric paired tests for pairwise comparisons of a measure were performed. Results Participants reported improved libido and sexual satisfaction as demonstrated by both the PROMIS-SF and FSFI data (see Table 1). 35/43 (83.3%) patients completed the FSFI and 25/43 (58.1%) completed the PROMIS-SF. The mean overall total FSFI score increased from 11 at baseline, to 17 at week 8 and 24 at week 36. The PROMIS data for interest in sexual activity improved from a baseline mean score of 43 to 51 at 8 weeks, to 54 at 24 weeks and 55 at 36 weeks. Similarly, the FSFI data in the domains of desire and arousal improved respectively from 1.90 and 1.56 at baseline to 3.03 and 3.05 at 8 weeks, 3.30 and 3.17 at week 16 and 3.53 and 4.01 at week 36. Satisfaction with sex life also improved from PROMIS baseline of 46 to 49 at week 8 and 55 at week 36. FSFI data for the domain of satisfaction indicate parallel trends with a baseline score of 2.36, increasing to 3.15 at week 8 and 4.45 at week 36. Furthermore, vaginal discomfort scores improved on both the PROMIS and FSFI. FSFI data on lubrication also showed improvement with a baseline mean score of 1.85 increasing to 2.84 by week 8, 3.24 at week 24 and 4.01 at week 36. However, the PROMIS suggests a decrease in lubrication from baseline to week 8. Patient distress also decreased throughout the study as measured on the FSDS-R and distress thermometer. There were no severe adverse events. The most common adverse events were nausea, somnolence and dizziness. Conclusions Flibanserin improves libido and overall sexual function as measured by the PROMIS-SF and FSFI in breast cancer patients on endocrine therapy. The exciting data from this pilot study is currently informing a larger randomized placebo-controlled study evaluating the efficacy of flibanserin in women with breast cancer. Disclosure Yes, this is sponsored by industry/sponsor: Sprout Pharmaceuticals Clarification: Industry funding only - investigator initiated and executed study Any of the authors act as a consultant, employee or shareholder of an industry for: Ms. Medicine, NanOlogy LLC, Paxman Cooling Ltd, Procter and Gamble, Rejoy, Revision Skincare, Sermonix, Shook, Hardy and Bacon, Spectrum Pharmaceuticals, Sprout Pharmaceuticals, TerSera.

A Study on Indian Mutual Funds

The Indian mutual fund industry performs a pivotal position in the U. S. A.'s monetary landscape, supplying a extensive spectrum of funding alternatives tailored to fulfill the numerous monetary desires and danger appetites of buyers. This studies paper goals to delve into the overall performance, strategies, and effect of mutual funds controlled via Asset Management Companies (AMCs) in India. It explores the variety of schemes available, inclusive of fairness funds, debt, liquid, gilt, and balanced funds, catering to each younger and pro buyer. The observe also examines the regulatory framework designed to defend traders' pastimes, emphasizing the enterprise's commitment to transparency and accountability. Furthermore, the paper investigates the evolving dynamics inside the mutual fund region, especially in light of growing competition among AMCs. It seeks to apprehend investor orientations in the direction of mutual budget, specializing in chance urge for food and alternatives for numerous schemes, plans, and alternatives regarding fee of returns, dividend frequency, and liquidity. Through comprehensive evaluation, the studies pursuits to provide insights that could manual AMC strategies and policies, in the end enhancing the overall investor revel in and fostering boom within the Indian mutual fund industry. KEYWORDS: Research Paper, NAV (Net Asset Value), SIP (Systematic Investment Plan), ELSS (Equity Linked Savings Scheme), AUM (Assets Under Management), Growth Option, Dividend Options.

Funding and conclusions of network meta-analyses on targeted therapies in inflammatory diseases: an overview

ObjectivesTo explore the association between industry funding and network meta-analyses’ (NMAs) conclusion, and the use in Clinical Practice Guidelines (CPGs) of NMAs. Study Design and SettingThis was an overview of NMAs and CPGs. We searched PubMed/MEDLINE, Epistemonikos, and several guideline databases up to February 18th 2023. We included CPGs from the last 5 years and NMAs of randomized controlled trials that evaluated targeted therapies in immune-mediated inflammatory diseases. Data extraction and outcome assessments were done in duplicate by independent authors. ResultsWe included 216 NMAs and 99 CPGs. 31% (67/216) were industry-funded. The proportion of industry-funded NMAs that cited one treatment as being best was 44% (25/57) compared to 26% (30/116) for nonindustry-funded (OR = 2.24 [1.15-4.39]; aOR = 1.76 [0.81-3.81]). The abstract's conclusion of 39/67 (58%) industry-funded and 69/149 (46%) nonindustry-funded NMAs were considered unsupported by the results (OR = 1.61 [0.90-2.89]; aOR = 1.40 [0.71-2.78]). All industry-funded NMAs that cited one treatment as best cited their own sponsored drug. 59/99 (60%) CPGs included at least one NMA, with 23/59 (39%) of them citing industry-funded NMAs. ConclusionsWe did not find evidence that industry-funded NMAs were more likely to have unsupported conclusions or to cite only one treatment as being best in their conclusions compared to non-industry-funded NMAs. However, almost all industry-funded NMAs favored their own treatments. Even though 40% of the CPGs did not rely on NMA, over a third of those who did used industry-funded NMAs. Limitations include the possible misclassification due to undisclosed funding and potential confounders that have not been accounted for.

Promoting equity in clinical research: The role of social determinants of health

ObjectiveThis study aims to investigate the association between social determinants of health (SDoH) and clinical research recruitment outcomes and recommends evidence-based strategies to enhance equity. Materials and MethodsData were collected from the internal clinical study manager database, clinical data warehouse, and clinical research registry. Study characteristics (e.g., study phase) and sociodemographic information were extracted. Median neighborhood income, distance from the study location, and Area Deprivation Index (ADI) were calculated. Mixed effect generalized regression was used for clustering effects and false discovery rate adjustment for multiple testing. A stratified analysis was performed to examine the impact in distinct medical departments. ResultsThe study sample consisted of 3,962 individuals, with a mean age of 61.5 years, 53.6 % male, 54.2 % White, and 49.1 % non-Hispanic or Latino. Study characteristics revealed a variety of protocols across different departments, with cardiology having the highest percentage of participants (46.4 %). Industry funding was the most common (74.5 %), and digital advertising and personal outreach were the main recruitment methods (58.9 % and 90.8 %). DiscussionThe analysis demonstrated significant associations between participant characteristics and research participation, including biological sex, age, ethnicity, and language. The stratified analysis revealed other significant associations for recruitment strategies. SDoH is crucial to clinical research recruitment, and this study presents evidence-based solutions for equity and inclusivity. Researchers can tailor recruitment strategies to overcome barriers and increase participant diversity by identifying participant characteristics and research involvement status. ConclusionThe findings highlight the relevance of clinical research inequities and equitable representation of historically underrepresented populations. We need to improve recruitment strategies to promote diversity and inclusivity in research.

Association of Scholarly Impact to Industrial Contributions Among Academic Interventional Radiologists

ObjectiveThe Physician Sunshine Act of 2010 aimed to increase public awareness of physician-industry relationships. Our objective was to evaluate whether there is an association between scholarly impact and industry funding among academic interventional radiologists. MethodsA database from a prior study with our group was used in which we had investigated H-indices among US interventional radiologists; academic rank, gender, institution, and geographic location were obtained. The Scopus database was queried to determine all physicians’ H-index. The CMS Open Payments database was used to determine industry payments from 2015 to 2021 for each interventional radiologist. ResultsH-index and professor rank positively and significantly correlated with industrial funding (H-index coefficient = $6,977, P < .001 and professor rank coefficient = $183,902, P = .003). Industry funding was found to be significantly different between all ranks. Among 830 academic interventional radiologists, the mean industrial funding of male physicians was $130,034, which was significantly higher than female physicians’ $28,166 (P = .00013). By academic rank, male primary investigators of associate professor and unranked position had higher industrial funding than female primary investigators (Wilcoxon test, P = .029 and P= .039, respectively). Professor and assistant professor ranks had no significant difference in industrial funding between male and female physicians (Wilcoxon’s test, P = .080 and P = .053, respectively). ConclusionScholarly activity as defined by the H-index and academic rank seem to have a positive association with industry funding of academic interventional radiologists.

Global disparities in immunotherapy clinical trials: A comprehensive analysis of low- and middle-income countries over the past decade.

1606 Background: Immunotherapy (IO) has largely impacted cancer treatment over the last decade, yet its accessibility and representation in clinical trials remain severely limited in low- and middle- income countries. We investigated the involvement of these countries in IO cancer trials, analyzing country-specific rates and influencing factors. Methods: Data was obtained from clinicaltrials.gov. Advanced search focused on cancer interventional studies from 12/31/2013 to 01/01/2024 with specific IO treatments. Only completed trials were included. Studies unrelated to immunotherapy or cancer were excluded. Country trial rates were calculated per 100k population. Statistical analysis used Chi-square test for nominal data. Results: Of 1593 trials, 1282 were included in the final analysis. Of world’s 217 countries and regions (World Bank) 72 (33.2%) participated in IO cancer trials in the last decade. Zero country from low-income group was involved in the trials. Only 2.4% (31) of all trials, included lower-middle-income countries (LMICs). Out of 54 LMICs, only 8 were represented: Ukraine, Philippines, India, Guatemala, Egypt, Vietnam, Morocco, and Eswatini (Swaziland). Ukraine led this group with 16 trials, while the remaining 7 were included in less than 10 trials each. Upper-middle-income countries (UMICs) were included in 21.3% (273) of trials. Out of 54 UMICs, 22 were involved in the trials; China led this group (174), followed by Russia (69), Brazil (52), Mexico and Turkey (41 each). Among the top 30 countries with the highest trial participation, none included LMICs, and only 5 were UMICs. Of 81 high-income countries (HICs) 42 participated in IO trials. USA was involved in over 65% of all trials (840), followed by Spain (222), France (193), and Canada (180). However, population-adjusted rates varied, with European HICs like Latvia (2.16), Belgium (1.09), Norway (0.87) among 25 other countries, showing higher rates than USA (0.25). Majority of trials done solely in one country were also from USA (65%), and China (79%). A significant link was found between the economic status of participating countries and the funding source of trials (p&lt;0.00001). Industry funded 28 of 31 (90%) trials in LMICs, indicating a reliance on industry funding in these regions. Industry favored adult-only over pediatric-inclusive trials (p&lt;0.0001). Out of 80 trials (6.24%) including children, 22 were industry-funded. Exclusively pediatric IO trials were only 4 (0.3%) of all IO trials. LMICs participated in 3.75% (3) of all pediatric-inclusive trials. Conclusions: Countries with low economic status and children with cancer from both low- and high-income areas are largely underrepresented in IO cancer trials globally. More inclusive IO trials across age groups and LMICs are vital to implement trial results in real-world settings and close the care gap.

The Evolution and Review of Regulatory Changes on Emerging Asian Mutual Fund Industry Post-Global Financial Crisis

The proposed research paper aims to explore the significant transformations in the mutual fund industry following the global financial crisis of 2007-2009, with a particular focus on regulatory changes and their effects on mutual fund performance and investor confidence. The study will examine how new liquidity related regulations, such as enhanced liquidity-related disclosures, have contributed to the industry's resilience and growth. Additionally, the paper will analyze the disparity in mutual fund objectives and compositions across different regions, specifically comparing the dominant markets of the United States, and Emerging Asian, markets. By investigating the evolution of open-ended and exchange-traded funds as the fastest-growing investment vehicles post-crisis, this research aims to provide a comprehensive understanding of the current state and future prospects of the global mutual fund industry.

Impact of industry funding on atrial fibrillation clinical trials: insights and implications

Abstract Background/Introduction Commercial industry is an important source of funding for atrial fibrillation clinical trials, the implications of which have not been analyzed. Purpose The purpose of this study is to describe the characteristics of contemporary AF clinical trials and to evaluate their association with funding source. Methods We systematically assessed all completed atrial fibrillation trials registered in ClinicalTrials.gov between conception to September 1, 2022, and extracted publicly available information including funding source, trial size, race, ethnicity, sex, intervention, location, and publication status. Trial characteristics were compared using the Wilcoxon rank sum test and Fisher’s exact test for continuous and categorical variables, respectively. Results Of the 253 clinical trials assessed, 171 (68%) reported industry funding. Industry funding was associated with a greater median total enrollment (172 vs. 80; P &amp;lt; 0.001), publication rate (56.7% vs. 42.7%; P = 0.04), participation in device trials (48.0% vs. 24.4%; P &amp;lt; 0.001), and multicontinental recruitment location (25.2% vs. 2.4%; P &amp;lt; 0.001) when compared to non-industry funded clinical trials. However, industry funding was not associated with a significant difference in median impact factor (7.7 vs. 7.7; P = 0.723) or median number of citations (60.0 vs. 29.0; P = 0.09). The overall proportion of industry funded trials did not change over time (P = 1.00) since inception of the ClinicalTrials.gov database. Participant demographics remained relatively uniform over time across both industry-funded and non-industry-funded trials. Conclusion(s). Industry funded clinical trials in atrial fibrillation are often larger, more frequently published, multicontinental, and device-focused. Industry funding was found to be associated with significant differences in study enrollment, publication metrics, and study interventions. Insights from this study inform trial design, regulation, and policy considerations in the evolving landscape of AF research.TableFigure

Cross-sectional examination of commercial milk formula industry funding of international, regional and national healthcare professional associations: protocol

IntroductionCommercial milk formula manufacturers often emphasise their role in supporting infant and young child nutrition and breastfeeding, but their commercial goals to increase volume and profit margin of formula sales...

Performance implications of hedging with industry ETFs

Extant research documents that hedge funds which bet on positive earnings surprises manage their sector risk by shorting industry exchange-traded funds (ETFs). We add to this literature by evaluating the performance of a hypothetical hedge fund that can anticipate positive earnings news. We construct return series for a naked strategy that only takes long stock positions and a hedged strategy that also holds short positions in industry ETFs around earnings announcements with positive content. Our main result is that hedging with industry ETFs improves fund performance based on various reward-to-risk ratios. This finding holds in various equity subsamples and both strategies tend to perform better among riskier stocks. Hedging with industry ETFs boosts fund performance compared to hedging with a broad market index.

Bank affiliation and lottery-like characteristics of mutual funds

This study investigates the impact of commercial bank affiliation on mutual funds' lottery-like characteristics. Existing literature has extensively explored the benefits or costs of commercial bank affiliation in the asset management industry. Using a sample of Chinese mutual funds between 2003 and 2019, we reveal that bank affiliation significantly decreases these characteristics, and this phenomenon exhibits better performance. Our evidence suggests that affiliated funds benefit from information advantages. Notably, affiliated funds attract cash inflows by enhancing their performance rather than catering to investors’ lottery preferences. These results emphasize the role of gambling behavior in the mutual fund industry by focusing on the significance of ownership, in this case, by commercial banks.

Crowding of international mutual funds

We study the relationship between crowding and performance in the active mutual fund industry. Using the equity holdings overlap of 17,364 global funds, we find that funds that crowd into the same stocks underperform passive benchmark funds by 1.4% per year. The negative returns to crowding can at least in part be explained by excess demand for liquidity and the associated discount for holding liquid stocks. We show that our measure of crowding contains novel information about performance that is not reflected in other variables that describe funds’ investment environment, such as fund size and style. Our findings suggest that crowding of investment opportunities is important for understanding diminishing returns.

Risk-Return Analysis of Select Tax Saving Mutual Funds

The Indian stock market has been in existence since 1875 bestowing lesser range of instruments from companies to invest their money through general public. Since then, the awareness of investment has gained momentum amongst the general public and investors have become curious and intuitive to park their funds in some instrument to attain or gain profit or handsome returns from companies and the market. With the advent of Unit Trust of India (UTI) being formed during 1964 by a special legislature to function under the regulatory and administrative control of Reserve Bank of India (RBI) , it brought an innovative financial thought to the mechanism of investment by investors. Mutual Fund industry boosted the investors’ confidence that upheld capital appreciation, protection, tax burden and promoted financial stability. The researcher attempted to analyse the risk and returns of select tax savings scheme of mutual funds and point out the best tax saving mutual fund amidst the 11 selected funds using parameters like standard deviation, beta, sharpe ratio and treynor ratios for a period of 90 months from 2016 to 2023 taking Net Asset Values published by AMFI and the closing values of Bombay Stock Exchange Standard &amp; Poor (BSE S &amp; P) Sensex and also by using MS Excel for computing all the parameters manually rather than the already published data by many other sources. It was examined that Quant Tax Direct Plan (Growth Option) has good indicators to prove its performance. The research findings can aide investors’ decision with numerous benefits ranging from savings, returns, gains and risk management.

Influence of Climate Change Adaptation Policies on Sheep Farming Viability in Australia

Purpose: The aim of the study was to analyze the influence of climate change adaptation policies on sheep farming viability in Australia. Methodology: This study adopted a desk methodology. A desk study research design is commonly known as secondary data collection. This is basically collecting data from existing resources preferably because of its low cost advantage as compared to a field research. Our current study looked into already published studies and reports as the data was easily accessed through online journals and libraries. Findings: Climate change adaptation policies in Australia have significantly influenced the viability of sheep farming in recent years. Research indicates that the implementation of targeted adaptation measures, such as improved pasture management and water conservation strategies, has helped mitigate the adverse impacts of climate change on sheep farming viability. Studies have shown that farms adopting these policies have experienced higher survival rates of livestock and increased profitability compared to those without such measures. Additionally, government support programs aimed at assisting sheep farmers in implementing climate adaptation strategies have been instrumental in enhancing the resilience of the sector. Unique Contribution to Theory, Practice and Policy: Adaptation theory in environmental economics, resilience theory &amp; theory of planned behavior (TPB) may be used to anchor future studies on analyze the impact of climate change on wheat yields in Australia. The enhancement of breeding programs focuses on practical genetic advancements to create drought and heat-resistant sheep varieties, addressing direct climate impacts on livestock. By advocating for government and industry funding for genetic research, the recommendations influence policy towards investing in long-term solutions for climate resilience.

Abstract PO1-10-12: Advancing Gender Equity: A Closer Look at Women's Representation in Leading Breast Cancer Clinical Trials

Abstract Introduction: Clinical trials serve as pivotal sources for evidence-based medicine, wielding substantial influence within the medical and scientific community. In recent years, heightened attention has been directed towards encouraging greater female involvement and advancing their representation across various domains of the medical field. Female oncologists tend to focus more over breast cancer as a subspeciality and focused practice. Consequently, this observational study seeks to assess the present status of gender equity in leading breast cancer clinical trials, with the aim of identifying potential concerns and mitigating future risks of bias. By delving into this analysis, we can shed light on the current landscape and pave the way for improved inclusivity and fairness in breast cancer research. Methodology: To examine the portrayal of female principal investigators (PIs) in breast cancer clinical trials over the past two decades, we conducted a thorough search of breast cancer clinical trials listed on ClinicalTrials.gov. Furthermore, we employed https://gender-api.com to assess the gender of each PI and calculate the experience in the medical field of the PI by subtracting the PI graduation year from the year of conducting the clinical trial. In addition, we gathered pertinent details concerning the PIs and the clinical trials, and subsequently subjected the data to univariate analyses to detect any noteworthy distinctions between male and female PIs. Results: Over the span of the past twenty years, a total of 9,145 cancer clinical trials were conducted, with 1,127 (12.32%) focusing specifically on breast cancer. Through our rigorous efforts, we managed to gather comprehensive information about the principal investigators (PIs) in 788 (69.92%) of these clinical trials. Notably, we discovered that 419 (53.17%) of these trials were led by female investigators. Upon scrutinizing the characteristics of the PIs, we observed several significant distinctions between male and female PIs. Female PIs exhibited a lower median age (57.0 vs. 60.0) and possessed less medical experience (17 vs. 22 years) compared to their male counterparts (P&amp;lt; 0.001). Furthermore, we found a substantial divergence in the funding sources for the clinical trials between the genders. Female-led trials received a lower percentage of industrial funding (13.1% vs. 24.2% for males, P&amp;lt; 0.001) but showcased a significantly higher percentage of university funding (38.7% vs. 28.0% for males, P&amp;lt; 0.001). Most of the clinical trials led by female PIs were categorized as phase 2 trials (82.8% vs. 66.8% for males) and were conducted in single centers (61.2% vs. 52.6% for males), demonstrating a noteworthy statistical difference (P&amp;lt; 0.001) in both cases. However, no statistically significant disparities were found between male and female PIs in terms of termination rates, publication rates, or the type of intervention utilized in the clinical trials. Furthermore, the ratio of females PI wasn’t different throughout the time as the liner regression model estimated effect was -0.009 with P= 0.065. Conclusions: The study shows the great effort done by female researchers, even though they have lower age, experience, and support from the industrial companies and lower opportunity to have bigger multicenter clinical trials, they still manage to have equivalent rate of termination and publication of the clinical trials showing their capability to lead clinical trials and the need to be supported to maintain the gender equity in leading the breast cancer clinical trials. However, female involvement in other cancer sites might be different and needs to be looked at. Citation Format: Abdulrahman Alhajahjeh, Ghayda’ Bader, Basil Abdin, Taima’ Bader, Saji Aweidah, Layla El-Amayreh, Hikmat Abdel-Razeq. Advancing Gender Equity: A Closer Look at Women's Representation in Leading Breast Cancer Clinical Trials [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-10-12.

EXPLORING THE DYNAMICS BETWEEN MUTUAL FUND AND INVESTORS BEHAVIOUR

The basic purpose is to know about the Mutual Fund Industry and to know the behavior of the Indian Investors regarding different investment tools. This project will provide me t he better platform to understand the History, Growth and various other aspects of Mutual Fund. It will also help me to understand the behavior of Indian investor regarding different inve stment tools. SEBI is the apex regulatory of capital markets. SEBI has enacted the SEBI (mutual fund) Regulations, 1996, which provides the scope of the regulation of the mutual fund in India. All Mutual funds are required to be mandatory registered with SEBI. The structure and formation of mutual funds, appointment of key functionaries, operation of the mutual funds, accounting and disclosure norms, rights and obligations of functionaries and investors, investment restrictions ,compliance and penalties are all defined under the SEBI regulations. Mutual funds have to send half yearly compliance reports to SEBI, and provide all information about their operations